As previously communicated, effective April 1, 2024, the following FDA-approved adalimumab biosimilars have been added to the Tufts Health RITogether pharmacy formulary at preferred status with prior authorization:
- Adalimumab-adbm
- Adalimumab-fkjp
- Hadlima
All other available FDA-approved adalimumab biosimilars and the reference product Humira (adalimumab) will be non-preferred products and non-covered effective April 1, 2024.
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer